share_log

EyePoint Pharmaceuticals | DEFA14A: Others

SEC ·  Apr 27 04:06
Summary by Futu AI
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
EyePoint Pharmaceuticals, Inc. has filed definitive additional materials with the United States Securities and Exchange Commission (SEC) on April 26, 2024. The materials are related to a proxy statement under Schedule 14A of the Securities Exchange Act of 1934. This filing, indicated by the form DEFA14A, is an amendment that includes further materials but does not require an additional filing fee. The document was filed by EyePoint Pharmaceuticals as the registrant and does not involve any third party filers. The nature of the additional materials was not specified in the announcement.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.